Recombinant human C1 esterase inhibitor and uses thereof
The present invention provides, among other things, methods and compositions for treating complement mediated disease. In some embodiments, recombinant human C1 esterase inhibitor proteins having similar or longer half-life than native plasma-derived human C1 esterase inhibitor, and methods of making the same are provided. In some embodiments, the invention provides a method for administering an effective amount of a recombinant human C1 esterase inhibitor protein to an individual who is suffering from or susceptible to a complement-mediated disease such that at least one symptom or feature of said complement-mediated disease is prevented and/or reduced in intensity, severity, or frequency.
1. A composition comprising a purified recombinant human C1 esterase inhibitor (rhC1-INH) having an amino acid sequence 100% identical to SEQ ID NO:1 or SEQ ID NO:2, wherein the purified recombinant rhCl-INH has a glycosylation profile comprising 10-20% neutral glycans, about 26% mono-sialylated glycans, about 35% di-sialylated glycans, about 17% tri-sialylated glycans, and about 5% tetra-sialylated glycans, and wherein the purified rhC1-INH has a half-life similar to or longer than plasma derived human Cl esterase inhibitor.
2. The composition of claim 1 , wherein the purified rhC1-INH has a half-life of 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, or 70 hours.
3. The composition of claim 1 , wherein the purified rhCl-INH has a half-life in the range of 80%-120% of the half-life of plasma-derived human Cl esterase inhibitor.
4. A pharmaceutical composition comprising the composition comprising the purified rhC1-INH protein of claim 1 , and a pharmaceutically acceptable carrier.
5. A kit comprising a pharmaceutical composition of claim 4 .
6. A method of producing a recombinant human Cl esterase inhibitor (rhCl-INH) comprising the steps of:
providing a host cell engineered to express the rhC1-INH having an amino acid sequence 100% identical to SEQ ID NO:1 or SEQ ID NO:2, wherein the purified recombinant rhCl-INH has a glycosylation profile comprising 10-20% neutral glycans, about 26% mono-sialylated glycans, about 35% di-sialylated glycans, about 17% tri-sialylated glycans, and about 5% tetra-sialylated glycans; and
culturing the host cell under conditions suitable for the cell to produce the rhC1-INH, wherein the conditions comprise feeding the cells with a culture medium comprising a glycosylation modulator for at least a period of time.
7. The method of claim 6 , wherein the cells produce the rhCl-INH protein at a specific productivity rate of greater than about 5 picogram/cell/day.
8. The method of claim 6 , wherein the cells produce the rhCl-INH protein at harvest titer of 5, 6, 8, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, or 300 mg per liter per day.
9. A method for large-scale production of a recombinant human C1 esterase inhibitor (rhC1-INH) protein in mammalian cells, comprising culturing mammalian cells expressing the rhCl-INH protein in suspension in a large-scale culture vessel, wherein the rhC1-INH protein has an amino acid sequence 100% identical to SEQ ID NO:1 or SEQ ID NO:2, wherein the purified recombinant rhCl-INH has a glycosylation profile comprising 10-20% neutral glycans, about 26% mono-sialylated glycans, about 35% di-sialylated glycans, about 17% tri-sialylated glycans, and about 5% tetra-sialylated glycans, and wherein the rhC1-INH has a half-life similar to or longer than human plasma derived Cl esterase inhibitor.